---
title: "Xarelto (rivaroxaban), all indications: Dosing and administration questions"
description: "Dosing and administration questions on Xarelto (rivaroxaban) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Administration, Switching anticoagulants, Surgery and procedures, and Dosing. Questions: Can Xarelto tablets be crushed or given through a feeding tube? How do you switch a patient to Xarelto from warfarin or another anticoagulant? How do you switch a patient from Xarelto to warfarin or another anticoagulant? When should Xarelto be stopped before surgery? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/xarelto/dosing-and-administration"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xarelto (rivaroxaban), all indications: Dosing and administration questions

Manufacturer: Janssen Pharmaceuticals, Inc.  
Prescribing information: [Xarelto](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf)  
Indication pages: [Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation)

## Administration

<a id="xarelto-crushing"></a>

### Can Xarelto tablets be crushed or given through a feeding tube?

> “For adult patients who are unable to swallow whole tablets, XARELTO tablets (all 
> strengths) may be crushed and mixed with applesauce immediately prior to use and 
> administered orally. After the administration of a crushed XARELTO 15 mg or 20 mg 
> tablet, the dose should be immediately followed by food. Administration with food is 
> not required for the 2.5 mg or 10 mg tablets [see Clinical Pharmacology (12.3)].”

Source: [XARELTO: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=5)

> “Administration of XARELTO tablets via nasogastric (NG) tube or gastric feeding 
> tube: After confirming gastric placement of the tube, XARELTO tablets (all 
> strengths) may be crushed and suspended in 50 mL of water and administered 
> via an NG tube or gastric feeding tube. Since rivaroxaban absorption is 
> dependent on the site of drug release, avoid administration of XARELTO distal to 
> the stomach which can result in reduced absorption and thereby, reduced drug 
> exposure. After the administration of a crushed XARELTO 15 mg or 20 mg tablet, 
> the dose should then be immediately followed by enteral feeding. Enteral feeding 
> is not required following administration of the 2.5 mg or 10 mg tablets [see 
> Clinical Pharmacology (12.3)].”

Source: [XARELTO: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=5)

> “Crushed XARELTO tablets (all strengths) are stable in water and in applesauce for 
> up to 4 hours. An in vitro compatibility study indicated that there is no adsorption 
> of rivaroxaban from a water suspension of a crushed XARELTO tablet to PVC or 
> silicone nasogastric (NG) tubing.”

Source: [XARELTO: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=5)

## Switching anticoagulants

<a id="xarelto-switch-to"></a>

### How do you switch a patient to Xarelto from warfarin or another anticoagulant?

> “Switching from Warfarin to XARELTO - When switching patients from warfarin to 
> XARELTO, discontinue warfarin and start XARELTO as soon as the International 
> Normalized Ratio (INR) is below 3.0 in adults and below 2.5 in pediatric patients to 
> avoid periods of inadequate anticoagulation.”

Source: [XARELTO: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=5)

> “Switching from Anticoagulants other than Warfarin to XARELTO - For adult and 
> pediatric patients currently receiving an anticoagulant other than warfarin, start 
> XARELTO 0  to  2  hours prior to the next scheduled administration of the drug 
> (e.g., low molecular weight heparin or non-warfarin oral anticoagulant) and omit 
> administration of the other anticoagulant. For unfractionated heparin being 
> administered by continuous infusion, stop the infusion and start XARELTO at the 
> same time.”

Source: [XARELTO: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=5)

Note: The pediatric INR threshold in the first passage applies to the pediatric indications, which are outside the atrial fibrillation indication.

<a id="xarelto-switch-from"></a>

### How do you switch a patient from Xarelto to warfarin or another anticoagulant?

> “No clinical trial data are available to guide converting patients from XARELTO to 
> warfarin. XARELTO affects INR, so INR measurements made during 
> coadministration with warfarin may not be useful for determining the appropriate 
> dose of warfarin. One approach is to discontinue XARELTO and begin both a 
> parenteral anticoagulant and warfarin at the time the next dose of XARELTO 
> would have been taken.”

Source: [XARELTO: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=5)

> “Switching from XARELTO to Anticoagulants other than Warfarin - For adult and 
> pediatric patients currently taking XARELTO and transitioning to an anticoagulant 
> with rapid onset, discontinue XARELTO and give the first dose of the other 
> anticoagulant (oral or parenteral) at the time that the next XARELTO dose would 
> have been taken [see Drug Interactions (7.4)].”

Source: [XARELTO: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=5)

Note: The first passage is the instruction for adults.

## Surgery and procedures

<a id="xarelto-surgery"></a>

### When should Xarelto be stopped before surgery?

> “If anticoagulation must be discontinued to reduce the risk of bleeding with 
> surgical or other procedures, XARELTO should be stopped at least 24 hours 
> before the procedure to reduce the risk of bleeding [see Warnings and 
> Precautions (5.2)]. In deciding whether a procedure should be delayed until 
> 24 hours after the last dose of XARELTO, the increased risk of bleeding should be 
> weighed against the urgency of intervention. XARELTO should be restarted after 
> the surgical or other procedures as soon as adequate hemostasis has been 
> established, noting that the time to onset of therapeutic effect is short [see 
> Warnings and Precautions (5.1)]. If oral medication cannot be taken during or 
> after surgical intervention, consider administering a parenteral anticoagulant.”

Source: [XARELTO: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=5)

## Dosing

<a id="xarelto-body-weight"></a>

### Does the Xarelto dose need to be adjusted for body weight?

> “Extremes in body weight (≤50 kg or ≥120 kg) did not influence XARELTO® exposure. Therefore, XARELTO® dosing does not need to be adjusted.”

Source: [XARELTO: Frequently Asked Questions (FAQs), captured 2026-11-13](https://www.xareltohcp.com/faqs/#general-questions:~:text=Extremes%20in%20body%20weight%20%28%E2%89%A450,not%20need%20to%20be%20adjusted.)

This passage is in a collapsed section of the page; select: Does the dose of XARELTO® need to be adjusted for patients’ body weight?

## Related pages
- [Medical information: Xarelto (rivaroxaban): All indications](https://www.evicenter.com/medical-information/xarelto)
- [Indication](https://www.evicenter.com/medical-information/xarelto/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/xarelto/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/xarelto/safety)
- [Specific populations](https://www.evicenter.com/medical-information/xarelto/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/xarelto/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/xarelto/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/xarelto/access-and-coverage)
